Literature DB >> 34918242

Phage T7 as a Potential Platform for Vaccine Development.

Chuan Loo Wong1, Chean Yeah Yong1, Khai Wooi Lee2.   

Abstract

Bacteriophages have been explored for their uses in vaccine development, due to the ease of propagation while displaying epitopes in high density. Bacteriophage T7 has been demonstrated to be useful in the production of potential vaccine candidates for various diseases, including influenza A, foot-and mouth disease (FMD), and cancers. In this chapter, we described the use of phage T7 to display potential foot-and-mouth disease virus (FMDV) epitope, from cloning to expression, purification, and immunization in a mouse model.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bacteriophage T7; Foot-and-mouth disease virus (FMDV); Mice immunization; Phage T7 display; Phage vaccine

Mesh:

Substances:

Year:  2022        PMID: 34918242     DOI: 10.1007/978-1-0716-1892-9_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  Immunogenicity of T7 bacteriophage nanoparticles displaying G-H loop of foot-and-mouth disease virus (FMDV).

Authors:  Hai Xu; Xi Bao; Yu Lu; Yamei Liu; Bihua Deng; Yiwei Wang; Yue Xu; Jibo Hou
Journal:  Vet Microbiol       Date:  2017-05-04       Impact factor: 3.293

2.  Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7.

Authors:  Geok Hun Tan; Khatijah Yusoff; Heng Fong Seow; Wen Siang Tan
Journal:  J Med Virol       Date:  2005-12       Impact factor: 2.327

3.  Selection of tumor-binding ligands in cancer patients with phage display libraries.

Authors:  David N Krag; Girja S Shukla; Guang-Ping Shen; Stephanie Pero; Taka Ashikaga; Susan Fuller; Donald L Weaver; Susan Burdette-Radoux; Christian Thomas
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.

Authors:  Caterina Bartolacci; Cristina Andreani; Claudia Curcio; Sergio Occhipinti; Luca Massaccesi; Mirella Giovarelli; Roberta Galeazzi; Manuela Iezzi; Martina Tilio; Valentina Gambini; Junbiao Wang; Cristina Marchini; Augusto Amici
Journal:  Cancer Immunol Res       Date:  2018-10-16       Impact factor: 11.151

5.  Pros and cons of phage therapy.

Authors:  Catherine Loc-Carrillo; Stephen T Abedon
Journal:  Bacteriophage       Date:  2011-03

6.  Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.

Authors:  Anne Bruttin; Harald Brüssow
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies.

Authors:  Girja S Shukla; David N Krag; Elena N Peletskaya; Stephanie C Pero; Yu-Jing Sun; Chelsea L Carman; Laurence E McCahill; Thomas A Roland
Journal:  Cancer Immunol Immunother       Date:  2013-06-05       Impact factor: 6.968

8.  Genetic immunisation against hepatitis B using whole bacteriophage lambda particles.

Authors:  John B March; Jason R Clark; Catherine D Jepson
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

Review 9.  A century of the phage: past, present and future.

Authors:  George P C Salmond; Peter C Fineran
Journal:  Nat Rev Microbiol       Date:  2015-11-09       Impact factor: 60.633

10.  A complete protocol for whole-genome sequencing of virus from clinical samples: Application to coronavirus OC43.

Authors:  Florence Maurier; Delphine Beury; Léa Fléchon; Jean-Stéphane Varré; Hélène Touzet; Anne Goffard; David Hot; Ségolène Caboche
Journal:  Virology       Date:  2019-03-09       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.